TEVA NDA for ecopipam gets FDA priority review
TEVA says the U.S. FDA accepted its new drug application for ecopipam and granted priority review for the investigational Tourette syndrome therapy in pediatric patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.